{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01919827",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CMM/FPI"
      },
      "Organization": {
        "OrgFullName": "Clinica Universidad de Navarra, Universidad de Navarra",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis",
      "OfficialTitle": "Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells",
      "Acronym": "CMM/FPI"
    },
    "StatusModule": {
      "StatusVerifiedDate": "May 2018",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 1, 2018",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "May 1, 2018",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "August 1, 2013",
      "StudyFirstSubmitQCDate": "August 6, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 9, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "May 2, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "May 3, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Clinica Universidad de Navarra, Universidad de Navarra",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Clinical Trial Phase I, open, multicentric, non randomized, study with escalating doses, to evaluate the safety and feasibility of treatment with mesenchymal stem cells in patients with diagnosis of idiopathic pulmonary fibrosis.\n\nPrimary endpoint: The aim is to evaluate the safety and feasibility of the endobronchial administration of mesenchymal autolog stem cells derived from bone marrow (BM-MSC)in patients with mild-to-moderate idiopathic pulmonary fibrosis.\n\nSecondary endpoint:Assess the possible effect of the infusion of BM-MSC in stopping the fall of pulmonary function in patients with mild-to-moderate idiopathic pulmonary fibrosis."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Idiopathic Pulmonary Fibrosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Idiopathic pulmonary fibrosis",
          "Stem cells",
          "Mesenchymal stem cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "17",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "MSC endobronchial infusion",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Endobronchial infusion of adult mesenchymal stem cells",
                "Biological: Autologous mesenchymal stem cells derived from bone marrow"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Endobronchial infusion of adult mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "MSC endobronchial infusion"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Autologous mesenchymal stem cells derived from bone marrow",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "MSC endobronchial infusion"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of participants with adverse side effects.",
            "PrimaryOutcomeDescription": "Number of participants with adverse side effects, and according to the level of severity:\n\nLow level: Increase in cough, fever or skin reactions\nMedium level: Infections not requiring hospital admission, mild alterations of renal or liver function\n\nHigh level: Death or major side effects requiring hospitalization:\n\nWorsening dyspnea with >=10% reduction in forced vital capacity, reduction in arterial pressure oxygen >= 10 mmHg and radiology progression between 3 months separated visits.\nNeed for hospitalization due to respiratory failure requiring mechanical ventilation, worsening in gases exchange or lung infection.\nCarcinogenesis at 12 months after the endobronchial infusion of mesenchymal stem cells.",
            "PrimaryOutcomeTimeFrame": "Up to 12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF",
            "SecondaryOutcomeDescription": "Measures of efficacy:\n\nFall in forced vital capacity as a continuous variable\nProgression of the disease defined by: Death, need for transplantation or deterioration in pulmonary function defined by fall in forced vital capacity (FVC) > 10% or in lung diffusion capacity (DLCO) > 15%.",
            "SecondaryOutcomeTimeFrame": "Up to 12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "INCLUSION CRITERIA:\n\nCapacity for signing informing consent and express the willing to fulfill all the requirements of the study protocol during the study.\nThe patients should be, in the researcher opinion, capable to fulfill all the requirements of the trial.\nMale or female patients, 30 to 80 years old, inclusive.\n\nDiagnosis of idiopathic pulmonary fibrosis according to the following criteria, based on the ATS/ERS Guidelines:\n\nDefinite or probable usual interstitial pneumonia confirmed by surgical lung biopsy.\nIn the absence of surgical lung biopsy, all the following:\n\ni. High resolution CT (HRCT) showing definite findings for idiopathic pulmonary fibrosis (FPI): bibasal reticular opacities with minimal ground glass opacities.\n\nii. Absence of other known causes of FPI including toxicity from drugs, environmental exposure or connective tissue diseases.\n\niii. Pulmonary function tests showing ventilatory restrictive pattern and/or impaired gas exchange (FVC and/or DLCO <90% of predicted)\n\nFVC ≥ 50% of predicted value with ratio of FEV1 to FVC ≥ 0.70.\nDLco (corrected for hemoglobin) ≥ 35% predicted value.\nCapability of performing a 6 minutes walk test at the time of inclusion.\n\nEXCLUSION CRITERIA:\n\nAny of the following:\n\nCurrent pregnancy or lactation.\nFindings that are diagnostic of an interstitial pneumonia or restrictive respiratory disease condition other than UIP.\nObstructive pulmonary disease defined by FEV1/FVC < 0,7 or significant emphysema on HRCT.\nEvidence of sustained improvement in FPI defined by improvement of respiratory function tests before inclusion, observed in >=2 test over the year prior to inclusion.\nActive or recent respiratory infection (less than 60 days before inclusion) or history of frequent exacerbations of IPF from an infectious cause (more than 2/year over the last 2 years)\nHospitalization in the 60 days prior to inclusion due to acute exacerbation of IPF.\nChronic cardiac failure (functional class NYHA III/IV) or left ventricular ejection fraction < 25%.\nChronically receiving corticosteroid more than 10 mg of prednisone or equivalent, immunosuppressors or antifibrotic agents, including pirfenidone, D-penicillamine, colchicine, ciclosporin A, TNF-alpha antagonists, imatinib, IFN-gamma, azathioprine, cyclophosphamide, within the 30 days prior to inclusion.\nThe patient requires hemodialysis, peritoneal dialysis or hemofiltration.\nHistory of malignancy, with the exception of skin squamous or basocellular carcinoma or cervix in situ carcinoma treated successfully.\nHistory of ethanol abuse within the year prior to inclusion\nThe patient is participating in a clinical trial which includes other drugs or research products within the 28 days prior to baseline assessment.\nComorbidities limiting life expectancy to less than 12 months from the baseline assessment.\nMedical or psychiatric condition serious or active which might interfere with the treatment of study, assessment or protocol fulfillment.\nPositive test for HBsAg, HCV antibody, syphilis screening essays, or HIV antibody at screening.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "30 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Servicio de Neumología, Clínica Universidad de Navarra",
            "LocationCity": "Pamplona",
            "LocationState": "Navarra",
            "LocationZip": "31008 Pamplona",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Servicio de Neumología. Hospital Universitario de Salamanaca",
            "LocationCity": "Salamanca",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "34195252",
            "ReferenceType": "derived",
            "ReferenceCitation": "Campo A, González-Ruiz JM, Andreu E, Alcaide AB, Ocón MM, De-Torres J, Pueyo J, Cordovilla R, Villaron E, Sanchez-Guijo F, Barrueco M, Nuñez-Córdoba J, Prósper F, Zulueta JJ. Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. ERJ Open Res. 2021 Jun 28;7(2). pii: 00773-2020. doi: 10.1183/23120541.00773-2020. eCollection 2021 Apr."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000011658",
            "ConditionMeshTerm": "Pulmonary Fibrosis"
          },
          {
            "ConditionMeshId": "D000054990",
            "ConditionMeshTerm": "Idiopathic Pulmonary Fibrosis"
          },
          {
            "ConditionMeshId": "D000005355",
            "ConditionMeshTerm": "Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafAsFound": "Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M13664",
            "ConditionBrowseLeafName": "Pulmonary Fibrosis",
            "ConditionBrowseLeafAsFound": "Pulmonary Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M27142",
            "ConditionBrowseLeafName": "Idiopathic Pulmonary Fibrosis",
            "ConditionBrowseLeafAsFound": "Idiopathic Pulmonary Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3003",
            "ConditionBrowseLeafName": "Idiopathic Pulmonary Fibrosis",
            "ConditionBrowseLeafAsFound": "Idiopathic Pulmonary Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}